These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19175716)

  • 61. Neutropenia in dogs receiving vincristine for treatment of presumptive immune-mediated thrombocytopenia.
    LaQuaglia KA; Robertson JB; Lunn KF
    J Vet Intern Med; 2021 Jan; 35(1):226-233. PubMed ID: 33421218
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficacy and toxicity of carboplatin in the treatment of macroscopic mesenchymal neoplasia in dogs.
    Pritchard C; Al-Nadaf S; Rebhun RB; Willcox JL; Skorupski KA; Lejeune A
    Vet Comp Oncol; 2023 Dec; 21(4):717-725. PubMed ID: 37705417
    [TBL] [Abstract][Full Text] [Related]  

  • 63. ABCB1-1Delta polymorphism can predict hematologic toxicity in dogs treated with vincristine.
    Mealey KL; Fidel J; Gay JM; Impellizeri JA; Clifford CA; Bergman PJ
    J Vet Intern Med; 2008; 22(4):996-1000. PubMed ID: 18537875
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Ultrasonographic evaluation of vincristine-induced gastric hypomotility and the prokinetic effect of mosapride in dogs.
    Tsukamoto A; Ohno K; Tsukagoshi T; Maeda S; Nakashima K; Fukushima K; Fujino Y; Takeuchi A; Tsujimoto H
    J Vet Intern Med; 2011; 25(6):1461-4. PubMed ID: 22092644
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Plasma Cytokeratin 18 and fecal Alpha-1 Antitrypsin concentrations in dogs with osteosarcoma receiving carboplatin chemotherapy.
    Taikowski K; Rudinsky AJ; Louke DS; Warry E; Fenger JM
    Vet Med Sci; 2021 Mar; 7(2):385-392. PubMed ID: 33222415
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Retrospective evaluation of toceranib phosphate (Palladia®) toxicity in cats.
    Merrick CH; Pierro J; Schleis SE; Sones EA; Wright ZM; Regan RC; Siedlecki CT; Bergman PJ
    Vet Comp Oncol; 2017 Sep; 15(3):710-717. PubMed ID: 27041701
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Evaluation of carboplatin sustained-release delivery system in dogs with cancer.
    Tansey Baldwin C; Zwahlen CH; Kirschner S; Nakamura RK
    Vet Med Sci; 2016 Aug; 2(3):147-153. PubMed ID: 29067189
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Biodynamic signatures from ex vivo bone marrow aspirates are associated with chemotherapy-induced neutropenia in cancer-bearing dogs.
    Marcum BA; Li Z; Turek JJ; Moore GE; Nolte DD; Childress MO
    Vet Med Sci; 2021 May; 7(3):665-673. PubMed ID: 33369129
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Frequency and Severity of Neutropenia Associated with Food and Drug Administration Approved and Compounded Formulations of Lomustine in Dogs with Cancer.
    Burton JH; Stanley SD; Knych HK; Rodriguez CO; Skorupski KA; Rebhun RB
    J Vet Intern Med; 2016; 30(1):242-6. PubMed ID: 26682700
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Risk factors associated with the onset of lomustine-induced neutropenia in tumour-bearing dogs.
    Treggiari E; Cossu G; Valenti P; Taylor A
    Vet Comp Oncol; 2022 Sep; 20(3):577-586. PubMed ID: 35249267
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Early tumor response to intraarterial or intravenous administration of carboplatin to treat naturally occurring lower urinary tract carcinoma in dogs.
    Culp WT; Weisse C; Berent AC; Reetz JA; Krick EL; Jackson DE; Kass PH; Clifford CA; Sorenmo KU
    J Vet Intern Med; 2015; 29(3):900-7. PubMed ID: 25900646
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Evaluation of adverse events in small-breed dogs treated with maropitant and a single dose of doxorubicin.
    Matsuyama F; Harada K; Fukazawa E; Ichimata M; Nakano Y; Kobayashi T
    J Vet Intern Med; 2022 Jul; 36(4):1409-1415. PubMed ID: 35524687
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A pilot study of chemotherapy combinations in rats: Focus on mammary cancer treatment in female dogs.
    Silva LP; Yamamoto PA; Machado MCA; Neves FMF; Azeredo FJ; Dos Santos Silva ACS; Hlavac N; de Melo Soares D; Godoy ALPC; Estrela-Lima A
    Res Vet Sci; 2023 Mar; 156():14-21. PubMed ID: 36738520
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs.
    Tjostheim SS; Stepien RL; Markovic LE; Stein TJ
    J Vet Intern Med; 2016 Jul; 30(4):951-7. PubMed ID: 27149912
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Haematologic toxicity in dogs with mast cell tumours treated with vinblastine/prednisolone chemotherapy with/without radiotherapy.
    Stiborova K; Treggiari E; Amores-Fuster I; Del Busto I; Killick D; Maddox T; Marrington M; Mason SL; Blackwood L
    J Small Anim Pract; 2019 Sep; 60(9):534-542. PubMed ID: 31245847
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Increased incidence of gastrointestinal toxicity in canine cancer patients treated with concurrent abdominal radiation therapy and toceranib phosphate.
    Prebble AR; Weishaar KM; Thamm DH; Leary D; LaRue SM; Martin T; Boss MK
    Vet Comp Oncol; 2022 Mar; 20(1):142-153. PubMed ID: 34310002
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Serum concentration and safety of intravenous drip versus subcutaneous administration of carboplatin in dogs.
    Iwano M; Sadahiro K; Maruo T; Kawarai S; Kayanuma H; Orito K
    J Vet Med Sci; 2021 May; 83(5):775-779. PubMed ID: 33716231
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Plasma cytokeratin-18 concentrations as noninvasive biomarker of early gastrointestinal toxicosis in dogs receiving toceranib.
    Kovac RL; Ballash G; Fenger J; London C; Warry E
    J Vet Intern Med; 2018 Nov; 32(6):2061-2068. PubMed ID: 30353992
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Hematologic changes associated with half-body irradiation in dogs with lymphoma.
    Axiak SM; Carreras JK; Hahn KA; Endicott MM; Parshley DE; King GK
    J Vet Intern Med; 2006; 20(6):1398-401. PubMed ID: 17186856
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The use of lithium carbonate to prevent lomustine-induced myelosuppression in dogs: a pilot study.
    Abrams-Ogg AC
    Can J Vet Res; 2011 Jan; 75(1):73-6. PubMed ID: 21461200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.